MS Australia is very pleased to learn that Roche have announced the approval of Ocrevus (ocrelizumab) by the Therapeutic Goods Administration (TGA) for use in Australia.
Ocrevus can be used in treatment of both patients with relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) to delay the progression of physical disability. It is administered by intravenous (IV) infusion every 6 months.
Roche has made two submissions to the Pharmaceutical Benefits Advisory Committee (PBAC), firstly, for Ocrevus in relapsing remitting multiple sclerosis (RRMS), and secondly, for Ocrevus in PPMS.
While Roche pursues broad public funding for Ocrevus, a Product Familiarisation Program (PFP) will be opened in the coming months, allowing RRMS patients to access Ocrevus.
Roche expects to receive the outcome for its PBAC submission for RRMS in August 2017, and the PBAC submission for PPMS in December 2017.
In the meantime, Ocrevus will be available for PPMS patients to purchase privately, in the coming months.
To read the full statement from Roche, click here.